Optimal methionine-free diet duration for nitrourea treatment: A phase I clinical trial

Nutrition and Cancer

Volumn 60, Issue 1, 2008, Pages 23-30

  Durando, Xavier ^a,b,c,d   Thivat, Emilie ^a,b,c,d   Farges, Marie Chantal ^b   Cellarier, Eric ^a,b,c,d   D'Incan, Michel ^e   Demidem, Aïcha ^c   Vasson, Marie Paule ^b   Barthomeuf, Chantal ^c   Chollet, Philippe ^a,b,c,d  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c INSERM   (France)

^d Centre d'Investigation Clinique   (France)

^e HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA INTERFERON; CHLOROETHYLNITROSOUREA; CISPLATIN; DACARBAZINE; FOTEMUSTINE; METHIONINE; PREALBUMIN; TEMOZOLOMIDE; VINDESINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; BODY WEIGHT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIET RESTRICTION; FEMALE; GLIOMA; HUMAN; LEUKOPENIA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUTRITIONAL STATUS; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; HUMANS; MALE; MELANOMA; METHIONINE; MIDDLE AGED; NEOPLASM METASTASIS; NITROSOUREA COMPOUNDS; NUTRITIONAL STATUS; OLIGODENDROGLIOMA; PATIENT COMPLIANCE; TREATMENT OUTCOME;

ANIMALIA;

EID: 38749138495     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701525877     Document Type: Article

References (34)

1. Anderson ME: Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111-112, 1-14, 1998.
2. Thomas T and Thomas TJ: Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58, 244-258, 2001.
3. Halpern BC, Clark BR, Hardy DN, Halpern RM, and Smith RA: The effect of replacement of methionine by homocystine on survival of malignant and normal adult mammalian cells in culture. Proc Natl Acad Sci USA 71, 1133-1136, 1974.
4. Stern PH and Hoffman RM: Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst 76, 629-639, 1986.
5. Breillout F, Antoine E, and Poupon MF: Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst 82, 1628-1632, 1990.
6. Guo HY, Herrera H, Groce A, and Hoffman RM: Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res 53, 2479-2483, 1993.
7. Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, et al.: Methionine dependency and cancer treatment. Cancer Treat Rev 29, 489-499, 2003.
8. Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B, and Poupon MF: Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 6, 643-653, 2000.
9. Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, et al.: Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 61, 4017-4023, 2001.
10. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, et al.: Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66, 1873-1878, 1990.
11. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, et al.: Metastatic melanoma: chemotherapy. Semin Oncol 29, 427-445, 2002.
12. Galanis E and Buckner JC: Chemotherapy of brain tumors. Curr Opin Neurol 13, 619-625, 2000.
13. Thivat E, Durando X, D'Incan M, Cure H, Mouret-Reynier MA, et al.: Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial. Anticancer Drugs 16, 1003-1007, 2005.
14. Goseki N and Endo M: Thiol depletion and chemosensitization on nimustine hydrochloride by methionine-depleting total parenteral nutrition. Tohoku J Exp Med 161, 227-239, 1990.
15. Morvan D, Papon J, Madelmont JC, and Demidem A: Methionine deprivation potentiates the effect of cystemustine treatment on B16 melanoma tumor in syngenic recipients. Abstract 3822, AACR Proceeding Vol. 33, p. 771, 2002.
16. Cure H, Souteyrand P, Ouabdesselam R, Roche H, Ravaud A, et al.: Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. Melanoma Res 9, 607-610, 1999.
17. Durando X, Thivat E, Roche H, Bay JO, Lemaire JJ, et al.: Cystemustine in recurrent high grade glioma. J Neurooncol 79, 33-37, 2006.
18. Lakshmanan FL, Perera WD, Scrimshaw NS, and Young VR: Plasma and urinary amino acids and selected sulfur metabolites in young men fed a diet devoid of methionine and cystine. Am J Clin Nutr 29, 1367-1371, 1976.
19. Minet-Quinard R, Van Praagh I, Kwiatkowski F, Beaujon G, Feillel V, et al.: Pre- and postoperative aminoacidemia in breast cancer: a study vs. matched healthy subjects. Cancer Invest 22, 203-210, 2004.
20. Buzby GP, Mullen JL, Matthews DC, Hobbs CL, and Rosato EF: Prognostic nutritional index in gastrointestinal surgery. Am J Surg 139, 160-167, 1980.
21. Lee HA and Hartley TF: A method of determining daily nitrogen requirements. Postgrad Med J 51, 441-445, 1975.
22. WHO handbook for reprinting results of Cancer Treatment. WHO Offset Publication N48 Neoplasma 20, 37-46, 1990.
23. Kwiatkowski F, Girard M, Hacene K, and Berlie J: SEM: a suitable statistical software adapted for research in oncology. Bull Cancer 10, 715-721, 2000.
24. Goseki N, Yamazaki S, Shimojyu K, Kando F, Maruyama M, et al.: Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. Jpn J Cancer Res 86, 484-489, 1995.
25. Cao WX, Cheng QM, Fei XF, Li SF, Yin HR, et al.: A study of preoperative methionine-depleting parenteral nutrition plus chemotherapy in gastric cancer patients. World J Gastroenterol 6, 255-258, 2000.
26. Epner DE, Morrow S, Wilcox M, and Houghton JL: Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. Nutr Cancer 42, 158-166, 2002.
27. Godeneche D, Rapp M, Thierry A, Laval F, Madelmont JC, et al.: DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells. Cancer Res 50, 5898-5903, 1990.
28. Thivat E, Durando E, Demidem A, Farges MC, Rapp M, et al.: A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer. Anticancer Res 27(4), in press, 2007.
29. Lee SM, Thatcher N, Dougal M and Margison GP: Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 67, 216-221, 1993.
30. Lee SM, Thatcher N, Crowther D and Margison GP: In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother Pharmacol 31, 240-246, 1992.
31. Theuer RC: Effect of essential amino acid restriction on the growth of female C57BL mice and their implanted BW10232 adenocarcinomas. J Nutr 101, 223-232, 1971.
32. Breillout F, Hadida F, Echinard-Garin P, Lascaux V, and Poupon MF: Decreased rat rhabdomyosarcoma pulmonary metastases in response to a low methionine diet. Anticancer Res 7, 861-867, 1987.
33. Kokkinakis DM, Schold SC Jr, Hori H, and Nobori T: Effect of long-term depletion of plasma methionine on the growth and survival of human brain tumor xenografts in athymic mice. Nutr Cancer 29, 195-204, 1997.
34. Sjolin J, Hjort G, Friman G, and Hambraeus L: Urinary excretion of 1-methylhistidine: a qualitative indicator of exogenous 3-methylhistidine and intake of meats from various sources. Metabolism 36, 1175-1184, 1987.